Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, discusses published insights from GPP patients.
Search
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Spotlight on GPP
Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
Innovation in medicinal chemistry
Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
Transboundary animal diseases (TADs)
Avian influenza? Bluetongue virus? FMD? Learn what are transboundary animal diseases and how they can impact us
Stargardt Disease
Stargardt Disease is a hereditary condition which causes degeneration of cells in the retina at the back of the eye.
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
A Clear Vision
Our vision is a future where earlier detection and individualized treatment will stop vision loss in its tracks, protecting and preserving eyesight, and way of life.
The Goals to Improve Living with GPP
An article that describes the current goals to improve the lives of those living with generalized pustular psoriasis
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Targeting MDM2-p53 in cancer: The story of brigimadlin
Learn about the discovery of Brigimadlin, our MDM2-p53 antagonist, that is being developed for the treatment of dedifferentiated liposarcoma, a rare cancer
Scleroderma Life Hacks
Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
Avian influenza 5 things you should know
Communities across the globe are faced with outbreaks of bird flu. We stand with poultry farmers and veterinarians and supports the effort against the disease
Podcast: Journeys through pulmonary fibrosis
As we speak to the courageous pulmonary fibrosis community, we hear heart-warming stories of determination, resilience and spirit.
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease
Living with pulmonary fibrosis and finding hope
From caregiver to co-founder of the European Pulmonary Fibrosis Federation, Liam Galvin shares about his experience, and the impact of ongoing research
GPP
GPP
FDA-approves-nintedanib-in-SSc-ILD
FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD